T-Therapeutics closes oversubscribed $133M Series B led by Advent Life Sciences and British Business Bank to advance first-in-class TCR bispecific therapies.
PRIVATENov 05, 2026
Amount Raised
$133 Million
Round Type
Series B
Biotechnology
Investors
BgfTencentSanofi VenturesCambridge Innovation CapitalDigitalis VenturesF PrimeSofinnova PartnersEli Lilly And CompanyM VenturesSamsara BiocapitalJohnson & Johnson InnovationBritish Business BankAdvent Life Sciences
Description
T-Therapeutics announced the closing of a $133 million Series B financing round co-led by Advent Life Sciences and British Business Bank. The round included participation from new investors Johnson & Johnson Innovation (JJDC), Samsara BioCapital, M-Ventures, and Eli Lilly, alongside all existing major shareholders including Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, and BGF. The proceeds will fund clinical development of two first-in-class TCR-CD3 bispecific programmes in cancer and autoimmune disease. Dr
Who to call at T-Therapeutics, and when
A new round usually means T-Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day T-Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at T-Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at T-Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
T-Therapeutics
About
T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.
We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment T-Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
